GRAIL, Inc. (GRAL)
About GRAIL, Inc.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $147.2M
- Net income
- -$408.4M
- Total assets
- $2.9B
- Market cap
- $2.9B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.9B
- Shares outstanding
- 20.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 12, 2024
GRAIL, Inc. (GRAL) Stock Price
- Reported a net loss of $408.4M in FY2025.
- Trading 9% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GRAIL, Inc..
Write a review
News about GRAIL, Inc.
News & sentiment via Polygon.io
GRAIL, Inc.: frequently asked questions
Is GRAIL, Inc. an American company?
GRAIL, Inc. is a US-based company headquartered in Menlo Park, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is GRAIL, Inc. headquartered?
GRAIL, Inc. is headquartered in Menlo Park, California, United States.
Is GRAIL, Inc. publicly traded?
Yes — GRAIL, Inc. is a publicly traded company. Its stock trades under the ticker symbol GRAL on the NASDAQ.
What does GRAIL, Inc. do?
GRAIL, Inc. is an American Medical Devices company in the Health & Beauty sector.
